Plasma Level of Mitochondrial DNA in Patients With ARDS and Its Clinical Significance

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02883231

Enrollment

Registered

2016-08-30

Start date

2016-04-30

Completion date

2017-03-31

Last updated

2016-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluate the Correlation Between the Level of Mitochondrial DNA in Plasma and the Prognosis of the Patients With ARDS.

Brief summary

To observe the changes of plasma mitochondrial DNA (mtDNA) levels in patients with ARDS, and to explore its clinical significance.

Detailed description

60 patients who diagnosed as ARDS were included in this study.Then keep blood samples from these patients in the first day、the third day and the sveventh day,detect the mitochotndrial DNA level in plasma by real-time quantitative PCR. Recored Severity of illness and survival status of every patient within 28 days.Objective to evaluate the correlation between the level of mitochondrial DNA in plasma and the prognosis of the patients.

Interventions

OTHERtaking peripheral blood

taking peripheral blood of no more than 3ml

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Patients admitted to ICU diagnosed of ARDS (Berlin criteria), 2. Patients age between 18 years old and 80 years.

Exclusion criteria

1. Pregnant women, 2. Patients with malignant tumor, 3. Immunosuppression or immunocompromised patients.

Design outcomes

Primary

Measure	Time frame
mortality	28-day

Countries

China

Contacts

Primary ContactLili Huang, Dr

caowangyou007@126.com13770840246

Backup ContactHaibo Qiu, Dr

haiboq2000@gmail.com+862583262550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026